BioMarin is a global pharmaceutical company focused on developing first-in-class and best-in-class therapeutics that provide meaningful advances to patients who live with serious and life-threatening rare genetic diseases. These conditions are often inherited, difficult to diagnose, progressively debilitating, have few, if any, treatment options and are usually ignored. Time is critical to patients with rare diseases, and BioMarin strive to quickly develop important therapies for them.

The Company's product portfolio comprises three approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® for mucopolysaccharidosis VI; Aldurazyme® for mucopolysaccharidosis I; and Kuvan® Tablets, for phenylketonuria.

Employee Rating

3.4More
TypePublic
HQSan Rafael, US
Founded1997
Size (employees)2,581 (est)+13%
Websitebiomarin.com
BioMarin Pharmaceutical was founded in 1997 and is headquartered in San Rafael, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at BioMarin Pharmaceutical

Philip Lo Scalzo

Philip Lo Scalzo

Senior Vice President, Chief Compliance Officer
Robert A. Baffi

Robert A. Baffi

Ph.D. Executive Vice President, Technical Operations
G. Eric Davis

G. Eric Davis

Executive Vice President, General Counsel and Secretary
Henry J. Fuchs

Henry J. Fuchs

M.D President, Worldwide Research & Development
Richard Ranieri

Richard Ranieri

Executive Vice President, Human Resources
Dan Spiegelman

Dan Spiegelman

Executive Vice President and Chief Financial Officer
Show more

BioMarin Pharmaceutical Office Locations

BioMarin Pharmaceutical has offices in San Rafael, Washington, Pittsburgh, Phoenix and in 29 other locations
San Rafael, US (HQ)
770 Lindaro St
Novato, US
105 Digital Dr
Mocoa, CO
96 Cra. 9
Kronberg im Taunus, DE
28 Westerbachstraße
Hong Kong, HK
Mass Mutual Tower 38 Gloucester Rd
Dublin, IE
Saint James House Adelaide Rd
Show all (34)
Report incorrect company information

BioMarin Pharmaceutical Financials and Metrics

BioMarin Pharmaceutical Revenue

Embed Graph
View revenue for all periods
BioMarin Pharmaceutical's revenue was reported to be $1.31 b in FY, 2017
USD

Revenue (Q3, 2018)

391.7m

Gross profit (Q3, 2018)

312.8m

Gross profit margin (Q3, 2018), %

79.9%

Net income (Q3, 2018)

(12.6m)

EBIT (Q3, 2018)

(15.7m)

Market capitalization (17-Jan-2019)

17.4b

Closing stock price (17-Jan-2019)

97.5

Cash (30-Sep-2018)

882.2m
BioMarin Pharmaceutical's current market capitalization is $17.4 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

548.5m751.0m889.9m1.1b1.3b

Revenue growth, %

37%18%26%

Cost of goods sold

95.7m129.8m152.0m209.6m241.8m

Gross profit

452.7m621.3m737.9m907.2m1.1b
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

136.9m151.6m191.8m176.8m203.3m250.5m208.9m236.7m300.0m279.9m303.7m317.4m334.1m373.4m372.8m391.7m

Cost of goods sold

28.1m22.8m31.2m29.9m32.8m39.9m36.7m43.1m51.6m50.7m50.0m56.3m59.5m82.3m79.0m78.9m

Gross profit

108.8m128.7m160.6m146.9m170.5m210.6m172.2m193.6m248.4m229.2m253.7m261.1m274.7m291.1m293.8m312.8m

Gross profit Margin, %

80%85%84%83%84%84%82%82%83%82%84%82%82%78%79%80%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

568.8m875.5m397.0m408.3m598.0m

Accounts Receivable

117.8m144.5m165.0m215.3m261.4m

Inventories

162.6m199.5m271.7m355.1m475.8m

Current Assets

1.1b1.4b1.1b1.4b2.2b
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Cash

181.6m639.8m584.7m398.0m900.6m440.7m376.3m270.5m306.0m707.3m348.2m354.9m431.4m474.0m427.4m882.2m

Accounts Receivable

124.7m110.5m122.3m121.4m175.7m186.1m148.9m180.8m214.2m215.9m230.3m238.3m251.9m318.4m363.6m384.3m

Inventories

148.7m176.9m193.5m204.4m222.8m237.5m262.1m297.0m326.6m347.4m384.1m429.8m457.4m468.2m473.4m508.5m

Current Assets

713.5m1.2b1.2b1.1b1.5b1.2b1.2b992.8m1.1b1.7b1.4b1.5b2.1b2.2b2.3b2.4b
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(176.4m)(134.0m)(171.8m)(630.2m)(117.0m)

Depreciation and Amortization

47.3m56.7m47.2m96.9m87.9m

Inventories

(33.9m)(37.0m)(51.0m)(64.5m)(96.9m)

Accounts Payable

20.4m90.3m(53.2m)45.5m
USDY, 2018

Financial Leverage

1.6 x
Show all financial metrics

BioMarin Pharmaceutical Operating Metrics

FY, 2016

Patent Applications

426

Patents Issued

1.17 k

Phase 1/2 Trials Products

2

Phase III Trials Products

2
Show all operating metrics

BioMarin Pharmaceutical Revenue Breakdown

Embed Graph

BioMarin Pharmaceutical revenue breakdown by geographic segment: 18.4% from Rest of the World , 13.3% from Latin America, 22.7% from Europe and 45.5% from United States

Report incorrect company information

BioMarin Pharmaceutical News and Updates

Report incorrect company information

BioMarin Pharmaceutical Blogs

BioMarin Highlights Key Milestones for 2019 at 37th Annual J.P. Morgan Healthcare Conference in San Francisco

Completed Enrollment of Subject Cohort to Support BLA Submission Through Accelerated Approval (AA) Pathway for Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A

BioMarin to Participate in Two Investor Conferences in November

- Credit Suisse 27th Annual Credit Suisse Healthcare Conference on November 13 in Scottsdale, AZ

BioMarin Highlights Breadth of Innovative Development Pipeline at R&D Day on November 7th in New Yorkwdxefcqufszuzezftuxetqsqxt

Vosoritide for Achondroplasia: Demonstrates Continued Increased Growth through 42 months in Phase 2; Global Phase 3 Fully Enrolled

BioMarin to Highlight Breadth of Innovative Development Pipeline at R&D Day on November 7th in New York

Key Research & Development Pipeline Products and Data to be Presented, Including:
Show more

BioMarin Pharmaceutical Company Life and Culture

Report incorrect company information

BioMarin Pharmaceutical Frequently Asked Questions

  • When was BioMarin Pharmaceutical founded?

    BioMarin Pharmaceutical was founded in 1997.

  • Who are BioMarin Pharmaceutical key executives?

    BioMarin Pharmaceutical's key executives are Philip Lo Scalzo, Robert A. Baffi and G. Eric Davis.

  • How many employees does BioMarin Pharmaceutical have?

    BioMarin Pharmaceutical has 2,581 employees.

  • What is BioMarin Pharmaceutical revenue?

    Latest BioMarin Pharmaceutical annual revenue is $1.3 b.

  • What is BioMarin Pharmaceutical revenue per employee?

    Latest BioMarin Pharmaceutical revenue per employee is $509 k.

  • Who are BioMarin Pharmaceutical competitors?

    Competitors of BioMarin Pharmaceutical include Mylan, Cesca Therapeutics and Celldex Therapeutics.

  • Where is BioMarin Pharmaceutical headquarters?

    BioMarin Pharmaceutical headquarters is located at 770 Lindaro St, San Rafael.

  • Where are BioMarin Pharmaceutical offices?

    BioMarin Pharmaceutical has offices in San Rafael, Washington, Pittsburgh, Phoenix and in 29 other locations.

  • How many offices does BioMarin Pharmaceutical have?

    BioMarin Pharmaceutical has 34 offices.